Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD-5991 is a potent and selective Mcl-1 inhibitor (IC50: 0.7 nM in FRET assay; Kd: 0.17 nM in SPR assay).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 3,650 | 5日内发货 | ||
5 mg | ¥ 11,980 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | 待询 | 5日内发货 |
产品描述 | AZD-5991 is a potent and selective Mcl-1 inhibitor (IC50: 0.7 nM in FRET assay; Kd: 0.17 nM in SPR assay). |
靶点活性 | MCL1:0.17 nM (kd), MCL1:0.7 nM |
体外活性 | AZD-5991 is selective for Mcl-1 (IC50: 0.72?nM, Ki: 200?pM) vs. Bcl-2 (IC50: 20?μM, Ki: 6.8?μM), Bcl-xL (IC50: 36?μM, Ki: 18?μM), Bcl-w (IC50: 49?μM, Ki: 25?μM), and Bfl-1 (IC50: 24?μM, Ki: 12?μM). MOLP-8, MV4-11, and NCI-H23 cells are treated with AZD5991 (EC50: 0.033, 0.024, 0.19?μM, respectively). AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 reduces the levels of Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines. |
体内活性 | A single intravenous (i.v.) dose of AZD5991 leads to a dose-dependent antitumor effect ranging from tumor growth inhibition (TGI) to tumor regression (TR). Ten days after treatment, AZD5991 shows 52% and 93% TGI at 10 and 30?mg/kg, respectively. At the same time point, AZD5991 at 60?mg/kg leads to 99% TR with no detectable tumors in 6 out of 7 mice, while complete TR is seen in 7 out of 7 mice in the 100?mg/kg dose group. AZD5991 also shows a dose-dependent duration of response with tumors in the 100?mg/kg group growing back later than those in the 60?mg/kg group. The magnitude of in vivo tumor efficacy is correlated with activation of caspase-3 in the tumor and concentration of AZD5991 in plasma. Treatment with AZD5991 was well tolerated at all dose levels with no significant bodyweight loss. A single dose of AZD5991 36 days after the first dose causes tumor regression in 4 out of 4 mice. In mice dosed with AZD5991 at 100?mg/kg on day 0 and day 1, tumors grow back later than those dosed with a single dose of AZD5991 at the same dose level. |
分子量 | 672.26 |
分子式 | C35H34ClN5O3S2 |
CAS No. | 2143061-81-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (37.19 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.4875 mL | 7.4376 mL | 14.8752 mL | 37.188 mL |
5 mM | 0.2975 mL | 1.4875 mL | 2.975 mL | 7.4376 mL | |
10 mM | 0.1488 mL | 0.7438 mL | 1.4875 mL | 3.7188 mL | |
20 mM | 0.0744 mL | 0.3719 mL | 0.7438 mL | 1.8594 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZD-5991 2143061-81-6 Apoptosis BCL AZD 5991 AZD5991 Inhibitor inhibitor inhibit